Is Resistance Futile? Competing Against AI Native RCM Platforms

Private equity keeps funding well-capitalized startups that promise a fully automated future, and you are left wondering whether your medical billing company can survive against an AI native RCM competitor with nine figures in the bank. Sean McSweeney challenges the fear and hype around AI native RCM platforms. He separates the investor pitch from operational reality and draws on his own early mistakes entering medical billing to explain why a company built from scratch may not be the unstoppable force it appears to be. What You'll Learn: What does AI native actually mean, and is it really all AI? Why do tech-first teams so often underestimate the complexity of billing and claims processing? How does building for yourself differ from selling one platform to everyone? What advantage might an existing operation have that a startup cannot buy? Competition from AI native RCM companies is real, but this episode makes the case that you do not need to panic about being wiped out overnight.